SFK Inhibitor
Glioblastoma
PreclinicalActive
Key Facts
About Lead Discovery Siena
Lead Discovery Siena is a private, preclinical-stage biotechnology company founded in 2015 (originating from a 2012 spin-off). It leverages a multi-faceted platform combining AI/machine learning, medicinal chemistry, and biological services to advance its own drug candidates and service client programs. The company's strategy is built on fostering local and international collaborations, with a pipeline featuring promising assets in glioblastoma and broad-spectrum antivirals, alongside a proprietary Antibody Drug Conjugate (ADC) linker technology.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |